An Anti-PD-1-GITR Ligand Bispecific Enhances Antitumor Immunity.
Cancer Discov
; 12(5): OF10, 2022 05 02.
Article
in En
| MEDLINE
| ID: mdl-35491629
A PD-1-directed, multimeric GITR agonist enhances immune cell activation to inhibit tumor growth.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasms
Limits:
Humans
Language:
En
Journal:
Cancer Discov
Year:
2022
Document type:
Article
Country of publication:
United States